IGC Pharma announces TGR-63 reduces agitation in ‘Alzheimer’s Mouse Model’

IGC Pharma announced additional positive results of preclinical studies investigating the Company’s newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer’s disease. Previously disclosed results demonstrate that TGR-63 may successfully alleviate plaque burden in Alzheimer’s cell lines and animal models. Plaques are a key hallmark and therapeutic target of Alzheimer’s disease. “While we continue to progress our Phase 2b trial of IGC-AD1 as a treatment for agitation in dementia due to Alzheimer’s, we are excited by the preclinical results of TGR-63, in particular the profound impact of the drug on plaques and on reducing anxiety in a transgenic Alzheimer’s mouse model. In line with IGC Pharma’s artificial intelligence and machine learning, AI/ML, initiatives, we plan to leverage cutting-edge AI/ML tools for studying TGR-63’s toxicology and protein interactions. By harnessing the power of AI/ML, we expect to accelerate the journey of TGR-63 from preclinical to patient care. We continue progressing IGC-AD1 and TGR-63 enthusiastically and anticipate clinical milestone updates throughout 2024 from our strengthened AD pipeline,” said CEO Ram Mukunda…The mice in the APP/PS1 group that received TGR-63 treatment showed significant improvements in their emotional well-being and anxiety levels compared to the group that didn’t receive treatment. A series of tests were used to measure these improvements. …The results from these multiple tests indicate that TGR-63 treatment helped normalize emotional and behavioral responses in our Alzheimer’s mouse model, reinforcing its potential as a promising treatment.